202 results about "Ferritin" patented technology

The invention discloses paenibacillus sp. H31, which is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC NO: M 20252669, and the preservation date is November 24, 2025. The invention further discloses a preparation method of the paenibacillus sp. The paenibacillus H31 disclosed by the invention not only has broad-spectrum disease-resistant activity on pathogenic fungi of various plants, but also has a remarkable growth-promoting effect on pepper, so that the paenibacillus H31 can be widely applied to prevention and treatment of agricultural diseases and insect pests, and sustainable development of green agricultural production is promoted. In addition, the paenibacillus H31 also has the effects of hydrolyzing proteinase and cellulose and decomposing ferritin, so that the paenibacillus H31 also can be applied to the scenes of industrial production and the like.

The invention discloses a method for screening high-yield recombinant human lactoferrin through nucleic acid aptamer-assisted mutagenesis of a trichoderma reesei strain and application, and belongs to the technical field of microorganisms. The nucleic acid aptamer Lac-6a-FAM-BHQ1 capable of changing the fluorescence intensity according to the content of lactoferrin is constructed on the basis of the aptamer Lac-6a, and the nucleic acid aptamer can be used for rapidly selecting a mutant strain for producing high-titer recombinant human lactoferrin. The ARTP mutagenesis technology is combined with a nucleic acid aptamer auxiliary screening system, the mutant strain with the improved recombinant human lactoferrin yield is rapidly obtained from a large number of mutant strains, and the yield reaches 274.57 mg / L and is improved by 24.8% compared with that of an original strain. After the genes 111681 and 62716 are over-expressed in T. reesei, compared with a control strain, the yields of the recombinant human lactoferrin of the recombinant strain are respectively increased by 6.9% and 22.1%.

Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.

The present invention belongs to the field of biomedicine. Provided are an influenza nanoparticle vaccine, and a preparation method therefor and the use thereof. A fusion protein containing an influenza virus strain HA protein or a fragment thereof, an antigenic epitope of the influenza virus protein, and ferritin, as an antigen, can induce an immune response effect against an influenza virus, and a vaccine composed of the fusion protein and an MF59 adjuvant can induce a protection effect against viral challenge and have a good cross-protection effect.

This invention provides an antimicrobial peptide spray, its preparation method, and its application in the prevention and treatment of peristomal skin infections. The spray comprises, by weight percentage, 0.05%-0.5% of a complex antimicrobial peptide, 0.1%-5% of a moisturizing and repairing film-forming matrix, 0.05%-0.2% of a buffer, 0.8%-1.2% of an isotonic regulator, 0.01%-0.5% of a stabilizer, and 0.005%-0.05% of a metal ion chelating agent, with the balance being water for injection. The complex antimicrobial peptide is composed of bovine lactoferrin antimicrobial peptide, sericin oligopeptide, and buckwheat-derived anti-inflammatory active peptide in a weight ratio of (3-5):(2-3):1. This spray possesses four core functions: broad-spectrum antibacterial activity, inhibition of bacterial biofilm, anti-inflammatory and soothing effects, and skin barrier repair. It is less likely to induce bacterial resistance, does not irritate damaged skin around the stoma, and can effectively prevent and treat peristomal skin infections.

A personalized supplement formulation system integrates biological data, structured qualitative feedback, and machine learning algorithms to generate individualized nutritional protocols. The system receives biological inputs such as genetic single nucleotide polymorphism (SNP) data, blood biomarkers (e.g., ferritin, vitamin D, B12), lipid profiles, and urinary metabolites. A digital user profile is created by organizing these inputs and calculating derived indices relevant to supplementation. Structured qualitative feedback, including dietary restrictions, perceived wellness, and training goals, is normalized and processed alongside the biological data. A trained machine learning engine analyzes combined inputs to output a tailored supplement formulation specifying ingredient selection, dosage, delivery format, and timing. Instructions are transmitted to a manufacturing system capable of producing the custom formulation. The system supports periodic re-evaluation and iteration based on new biological samples or user-reported feedback, enabling dynamic personalization over time and improving efficacy, compliance, and outcome tracking in athletic and wellness domains.

The invention discloses a magnetic-aptamer targeting tumor tissue nano-drug delivery system as well as a preparation method and application thereof, and belongs to the field of medicines. The system comprises a mesoporous ferroferric oxide magnetic core, a polyethyleneimine (PEI) layer coated outside the mesoporous ferroferric oxide magnetic core and an aptamer adsorbed outside the PEI layer, and an autophagy activator can be selectively loaded in the mesoporous core. The preparation method comprises the following steps: sequentially carrying out drug loading, PEI coating and aptamer modification on the mesoporous Fe3O4 nanoparticles. According to the invention, efficient enrichment and endocytosis of tumor tissues are realized through dual effects of magnetic targeting and active targeting of the aptamer; lysosome escape is promoted by using the proton sponge effect of PEI; finally, by virtue of the synergistic effect of iron ions released by degradation of the Fe3O4 nanoparticles and endogenous iron ions released by ferritin autophagy induced by an autophagy activator, ferroptosis of tumor cells is induced through enhanced Fenton-like reaction, so that high-efficiency and low-toxicity targeted therapy is realized.

The application discloses application of a human lactoferricin peptide in anti-inflammatory soothing and skin barrier repair. The application relates to the field of biotechnology, and provides application of a polypeptide or a biological material related to the polypeptide in preparation of a product with anti-inflammatory soothing and / or skin barrier repair functions; the polypeptide is a human lactoferricin peptide derived from a filtrate of a yeast fermentation lysate product, and an amino acid sequence of the polypeptide is shown as SEQ ID NO:1. The polypeptide has intervention potential on inflammation related to dermatitis and eczema, especially on atopic dermatitis. The polypeptide can be applied to the fields of medicines and cosmetics.

The application discloses a LYTAG-Gem compound for enhancing the anti-tumor effect of gemcitabine and application thereof, relates to the technical field of biological medicine, and particularly relates to a gemcitabine (Gem) targeted delivery system based on a lysosome targeting chimera (LYTAC) and application thereof in enhancing the anti-tumor process. 2+ The system is assembled from heavy chain ferritin, Ni 2+ , NTA-PEG5000-DBCO and a targeting ligand TPP-1-N3 in a specific mass percentage, can efficiently load Gem and form a nano compound with a particle size of about 59-79 nm, the system targets tumor cells through heavy chain ferritin, and realizes site-specific release of Gem in cells by means of an endocytosis-lysosome pathway mediated by the LYTAC structure, in-vivo pharmacodynamic experiments show that the LYTAC-Gem compound can significantly inhibit the tumor growth of a KPC pancreatic cancer mouse model, molecular mechanism research further reveals that the LYTAC-Gem compound can down-regulate the expression of PD-L1 protein in tumor tissues, and it is indicated that the LYTAC-Gem compound has the potential to activate an anti-tumor immune response, and the application provides a novel targeted delivery strategy for overcoming the toxic side effects and tumor drug resistance of gemcitabine.

This invention discloses a NK cell culture kit, its culture method, and its application. The kit includes an amplification medium, a high-efficiency induction medium, an NK-A coating solution, an NK-B mixture, and an NK-C mixture. The amplification medium contains basal medium, NAD+, human serum albumin, transferrin, β-glucan, glutathione, β-mercaptoethanol, and linoleic acid. The high-efficiency induction medium, in addition to the amplification medium components, contains soybean peptides, nicotinamide, inulin, and N-acetyl-L-cysteine. The NK-A coating solution contains heparin sodium, monoclonal antibodies, and antibodies. The NK-B mixture contains Inbakicept, IL-2, and IL-15. The NK-C mixture contains linolenic acid, IL-2, and IL-18. The Inbakicept factor in the kit can activate NK cells and enhance their cytotoxicity; linolenic acid can inhibit T cell proliferation, increase NK cell purity, and enhance cell efficacy.

This invention relates to the field of pet care product technology, and discloses a pet oral care spray and its preparation method. The preparation method employs a low-temperature gradient stepwise dissolution process: glucose oxidase is pre-dissolved at low temperature to obtain pre-solution A; bovine colostrum powder and lactoferrin are dissolved at low temperature to obtain protein pre-solution B; honey, folic acid, and vitamin D3 are dissolved at room temperature to obtain excipient pre-solution C; lysozyme is added to protein pre-solution B and stirred to dissolve; then pre-solution A and excipient pre-solution C are combined sequentially, the pH is adjusted, and purified water is added to make up the volume; the mixture is filtered through a microporous membrane for sterilization, and then filled and sealed under inert gas protection. This preparation method effectively protects the biological activity of each active protein and enzyme, achieving a long shelf life without the need for additional chemical preservatives. The resulting spray does not contain irritating ingredients such as alcohol and menthol, and is suitable for improving stomatitis, inhibiting plaque and tartar, and alleviating halitosis in pets of all ages and breeds.

This application discloses a sheep milk probiotic formula milk powder that can regulate intestinal flora and its preparation method. By weight, it contains the following raw material components: 600-700 parts sheep milk base, 5-15 parts compound probiotic powder, 30-60 parts prebiotic composition, 10-30 parts functional additives, and 5-20 parts nutritional fortifiers. This compound formula combines multiple probiotics and optimizes the strain ratio to achieve a synergistic colonization effect. The probiotics are prepared using a freeze-drying process, effectively improving problems caused by flora imbalance. Simultaneously, multiple compound prebiotics provide nutritional support for the proliferation of beneficial bacteria, synergistically enhancing the intestinal regulatory effect. Added functional components such as lactoferrin, chitosan, β-glucan, and poria cocos polysaccharide make it suitable for long-term conditioning consumption by sub-healthy individuals and those with weak digestive systems. The raw sheep milk undergoes vacuum distillation to remove the muttony odor. A process of wet powdering followed by aseptic dry mixing of probiotics is used, resulting in a more stable overall quality of the finished product.

The invention discloses an improved loading method of a nano-drug carrier, which comprises the following steps: adding a carrier of recombinant human heavy-chain ferritin or a derivative thereof into a high-concentration urea solution, mixing and reacting to depolymerize a shell of the recombinant human heavy-chain ferritin; adding a medicine, mixing and incubating; and diluting a reaction solution obtained by incubation into a low-concentration urea solution by using a Tris buffer solution, reacting for 8-15 hours to re-polymerize the recombinant human heavy chain ferritin shell, and finally changing the solution by using a membrane bag with the molecular weight cutoff of 50 KD through the Tris buffer solution to obtain the loaded ferritin drug composite particles. According to the preparation method provided by the invention, the effect of obviously improving the protein recovery rate and the drug loading capacity is achieved by providing a preparation method of replacing liquid after dilution and then standing and optimizing the drug-mass ratio, the protein recovery rate can reach 100%, and the drug loading capacity can reach 186 mu g / mL.

This invention provides the application of gonococcal ferritin in the preparation of anti-gonococcal products, relating to the field of antibody technology. The application of gonococcal ferritin subunits in the preparation of antibodies against gonococcal ferritin inhibits gonococcal infection by intervening in the iron metabolism pathway of gonococci, without inducing classic drug resistance mutations. This overcomes the limitations of existing technologies that rely on antibiotics, achieving broad-spectrum inhibition of drug resistance lineages. It solves the technical problem in existing technologies where multidrug / pan-drug resistance of gonococci leads to complete failure of antibiotic treatment, and the lack of therapeutic targets targeting its core survival mechanisms.

The application discloses a complex preparation containing bovine lactoferrin and lyticase and application thereof, and belongs to the technical field of biology. The preparation is composed of bovine lactoferrin and streptococcal lyticase, and both are prepared through a baculovirus-insect cell eukaryotic expression system. Researches show that the complex preparation has a significant synergistic antibacterial effect. The complex preparation not only can effectively inhibit a plurality of gram-positive bacteria, but also can overcome the limitation that single streptococcal lyticase has weak activity on gram-negative bacteria, and significantly enhances the inhibiting effect on escherichia coli and salmonella. Especially, the complex preparation still has clear in-vitro antibacterial activity on multi-drug resistant escherichia coli such as ciprofloxacin and doxycycline, thereby providing a new way for developing a new type of drug for resisting drug-resistant bacteria.

The present invention relates to glycosylate HIV timer nanoparticles fused to self-assembling ferritin proteins which may be utilized as immunogens to enhance trafficking to lymph nodes and germinal centers and to heighten immune responses.

The invention discloses a bovine I-type tau interferon-ferritin fusion protein as well as a mutant and application thereof. The bovine I-type tau interferon is fused with a ferritin subunit, and interferon molecules are highly repeatedly and orderly displayed on the surface of a ferritin nanocage by utilizing the self-assembly characteristic of ferritin, so that a conformation suitable for the ferritin nanocage to play functions is formed, and the expression level, the structural stability and the antiviral activity of the tau interferon are remarkably improved. The fusion protein is subjected to rational design mutation to obtain a single-site or multi-site mutant with significantly improved antiviral activity and stability. According to the invention, a silkworm or insect cell eukaryotic expression system is adopted to express the fusion protein or the mutant thereof, and the expression system is safe to operate, simple and convenient in procedure, low in cost and extremely beneficial to large-scale industrial production; the prepared fusion protein or mutant nanoparticles can be applied to preparation of a plurality of drugs for preventing or treating bovine viral infection, tumors and immune system diseases and immunologic adjuvants for vaccine compatibility.

The application discloses a multi-effect repairing and anti-allergy toothpaste composition and a preparation method thereof. The toothpaste comprises the following raw material components in percentage by mass: hydroxyapatite 1.0-10.0%, zeolite 0.02-0.8%, vitamin E 0.02-0.5%, lactoferrin 0.0005-0.02%, and the rest is base. When harmful bacteria form a biofilm in the oral cavity, the zeolite can destroy the biofilm formed by the harmful bacteria, so that the vitamin E and the lactoferrin enter the biofilm. The lactoferrin adsorbs iron ions near the harmful bacteria, so that the harmful bacteria cannot form a biofilm again. After rinsing, a large amount of water can take away the harmful bacteria, and finally the hydroxyapatite repairs. The effective synergistic closed loop of the hydroxyapatite, the zeolite, the vitamin E and the lactoferrin reconstructs a healthy oral micro-ecology from the source.

The invention relates to an infectious bronchitis subunit vaccine based on a nano-skeleton technology. Specifically, the invention provides a fusion protein which sequentially comprises an infectious bronchitis virus S protein fragment or a mutant thereof, a connecting peptide and helicobacter pylori ferritin from an N terminal to a C terminal, wherein the infectious bronchitis virus S protein fragment is S1 protein, and the amino acid sequence of the S protein fragment is as shown in SEQ ID NO. 2; the mutant of the chicken infectious bronchitis virus S protein fragment is S1-2 protein or S1-3 protein, the amino acid sequence of the S1-2 protein is shown as SEQ ID NO.4, and the amino acid sequence of the S1-3 protein is shown as SEQ ID NO.5. The invention further discloses a preparation method of the chicken infectious bronchitis virus S protein fragment.

The invention discloses nanoparticles for tumor chemotherapy and immune combined treatment as well as a preparation method and application of the nanoparticles, and belongs to the technical field of biological medicines. The nanoparticles are rHF (at) Cel nanoparticles formed by wrapping tripterine (Cel) with recombinant human heavy chain ferritin (rHF). The preparation method comprises the following steps: obtaining recombinant rHF protein, mixing and assembling Cel and rHF under specific pH and temperature conditions, and purifying to obtain the recombinant rHF protein. The nanoparticles can effectively target tumor cells and release Cel to kill tumors; meanwhile, the rHF carrier can induce polarization of tumor-related macrophages from a tumor-promoting M2 type to an anti-tumor M1 type, reduce the proportion of regulatory T cells (Treg) in a tumor microenvironment and reverse an immunosuppression microenvironment. In-vitro and in-vivo experiments prove that the rHF (at) Cel nanoparticles have a remarkable killing effect on breast cancer cells and can effectively inhibit the growth of transplanted tumors of mice.

Provided are use of a bioactive protein in the preparation of a drug for treating herpes virus infection and a pharmaceutical composition for treating herpes virus infection. The pharmaceutical composition mainly comprises a bioactive protein, a matrix, a humectant, a pH regulator, and a preservative. The present invention has the following technical effects: 1) By means of a large amount of research and experimental verification, the inventors have discovered for the first time that anhydridized lactoferrin, a modified bioactive protein, has an inhibitory effect on herpes zoster virus (VZV). 2) In the pharmaceutical composition, the type and amount of excipient and the proportion of the main ingredient are reasonable. The pharmaceutical composition is administered in ointment form, in spray form, or in other dosage forms suitable for external use, has a significant therapeutic effect, has small local toxic side effects, has very low acute dermal toxicity, causes no irritation or allergy, does not interfere with normal skin functions, and is safe and effective.

The application discloses a novel lactoferrin inducible soluble expression system and a construction method thereof, and belongs to the technical field of biotechnology and genetic engineering, and the specific scheme is that human lactoferrin (LF) is expressed by probiotic Escherichia coli Nissle1917, the protein is purified after the expression position is determined, and anti-inflammatory activity is determined. The LF expression system constructed by the application provides a construction method of a prokaryotic expression stable human lactoferrin expression vector, the vector is introduced into probiotic Escherichia coli Nissle1917, soluble target recombinant human lactoferrin is obtained after induction fermentation expression, two-step purification and identification, and the application has the characteristics of high safety, low cost, easy operation and the like.

The application provides an optimized lactoferricin peptide, a preparation method thereof and application thereof in preparation of anti-inflammatory and anti-oxidative damage preparations, and belongs to the technical field of biological medicines.The application obtains high-biological-activity lactoferricin peptide by optimizing amino acid sites of lactoferricin B; compared with the original lactoferricin B, the optimized lactoferricin peptide has better anti-inflammatory and anti-oxidative effects, can effectively reduce alcohol-induced oxidative damage, fatty degeneration and apoptosis of liver cells, and promote recovery of liver function.The lactoferricin peptide provided by the application can reduce the elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels by about 25% and 20%, respectively.The application provides an application scheme in development of a new generation of polypeptide drugs for treating alcoholic liver disease, hepatitis, acute lung injury and various inflammation oxidative stress related diseases.

This invention discloses a Bacillus amyloliquefaciens strain expressing bovine lactoferrin, its construction method, and its applications, belonging to the field of bioengineering technology. This invention utilizes the highly efficient protein secretion capacity of Bacillus amyloliquefaciens NFΔSE and the constitutive expression vector pMA5 for recombinant expression of bovine lactoferrin. Further, extracellular secretory expression of lactoferrin is achieved through signal peptide screening, and efficient fermentation synthesis of lactoferrin is realized in a fermenter through strategies such as optimized combined nutrient conditions and enhanced iron supply. Compared to traditional extraction processes, this process can produce lactoferrin through fermentation using this recombinant strain, effectively improving lactoferrin production capacity and demonstrating good industrialization potential.

The present application relates to natural ferritin, and particularly relates to an intracellular delivery system and application thereof. The system can effectively deliver various proteins into cells and maintain the biological activity thereof, and provides important technical support for the development of protein therapy with intracellular target as core. The method exhibits significant advantages in promoting intracellular protein transport, intracellular protein interaction research and protein level regulation. The delivery system has wide applicability, is simple to operate and safe and reliable, and becomes an important tool for future intracellular protein research and application.

This invention discloses a kitten food without palatability enhancers and its preparation method, relating to the field of pet food technology. It comprises the following components: polypeptide chicken meal, soy protein peptides, gluten hydrolysate, lactoferrin, astragalus extract, yam powder, rosemary oil, resveratrol, tributyrate, and rice. By adding substances containing small peptides and plant extracts to the kitten food, this invention provides the body with a large amount of high-quality animal protein without adding any chemically synthesized palatability enhancers, preservatives, or other chemical additives. This effectively promotes the body's decomposition and metabolism of nutrients, promotes the growth of kittens, and also enhances the body's antioxidant capacity and reduces the occurrence of diarrhea.

The invention belongs to the technical field of genetic engineering, and particularly relates to a bovine group A rotavirus multi-epitope fusion protein and application thereof. The invention provides a bovine group A rotavirus multi-epitope peptide based on a ferritin nano-carrier, a fusion protein and application of the bovine group A rotavirus multi-epitope peptide and the fusion protein. The multi-epitope peptide disclosed by the invention is a multi-epitope fusion antigen which is formed by splicing cytotoxic T lymphocyte epitopes, helper T cell epitopes and B cell epitopes with high conservative property and strong immunogenicity and is formed by screening and obtaining the cytotoxic T lymphocyte epitopes, helper T cell epitopes and B cell epitopes with high conservative property and strong immunogenicity on the basis of VP4 and VP7 protein sequences of bovine group A rotaviruses by utilizing an immunoinformatics technology. Immunological evaluation shows that the monoclonal antibody has good antigen specificity and neutralizing activity. Animal experiment results show that the epitope peptide and the fusion protein can induce an organism to generate high-level neutralizing antibodies aiming at BRVA G6, G8, G10 and other multi-genotype strains, and the broad spectrum and durability of immune protection are remarkably improved.

The present application relates to the Pichia pastoris fermentation medium and fermentation method for expressing recombinant bovine lactoferrin, and belongs to the technical field of biochemistry, which solves the technical problem of improving the expression amount of bovine lactoferrin in the process of industrialized and large-scale preparation of recombinant bovine lactoferrin. The components and their proportions in the Pichia pastoris fermentation medium aqueous solution for expressing recombinant bovine lactoferrin are as follows: yeast extract 10-30 g / L, phosphoric acid aqueous solution 25-35 g / L, calcium sulfate 1.0-3.0 g / L, potassium sulfate 18-22 g / L, potassium hydroxide 4.0-5.0 g / L, glycerol 30-50 g / L, magnesium sulfate heptahydrate 7-13 g / L, ammonium chloride 4-5 g / L, PTM1 trace element solution 4-6 ml / L, and defoaming agent 1-2 ml / L. The high-density fermentation method of the present application is realized by controlling the technical parameters such as the dissolved oxygen amount, pH value, temperature and feeding medium rate in the fermentation process, so that the expression amount of bovine lactoferrin is improved to 4-5 g / L.

The objective is to provide a simple and indirect method for estimating the rate of senescent immune cells (the ratio of immune cells with high SAβgal expression levels among T cells whose surface marker is CD8-positive) using a small amount of blood sample. [Solution] This method estimates the rate of senescent immune cells using the relative expression levels of one or more selected from Granzyme K, α-Klotho, GDF15, PAI-1 (SERPIN1), and ferritin in the blood.

The invention belongs to the technical field of biomedical detection, and particularly discloses a nerve injury early warning method and system for abnormal metabolism of iron ions, and the method comprises the steps: synchronously obtaining the steady-state real-time dynamic data of the iron ions and the multi-dimensional biomarker data of the autophagy activity of ferritin; a data basis for comprehensively reflecting the iron metabolism state is constructed; the complex coupling relation between the iron ion steady state and the ferritin autophagy is deeply analyzed through an iron metabolism abnormality coupling analysis model, a nonlinear pathological mode under the synergistic effect of the iron ion steady state and the ferritin autophagy is disclosed, and the accuracy and reliability of early warning decision making are improved; by analyzing the specific mode of iron ion metabolism abnormal state coding, identifying key driving factors causing risks, combining with the early warning level of nerve injury and matching with an individualized intervention scheme, closed-loop design from early warning to accurate intervention is realized, operable guidance is provided for clinical practice, and the method is suitable for popularization and application. And conversion from passive treatment to active defense is realized.